The appropriate lower limit for the percentfree prostate-specific antigen reflex range

Urology

Volumn 52, Issue 3, 1998, Pages 450-454

  Carlson, Grant D ^a   Calvanese, Christina B ^a   Childs, Stacy J ^a  

^a Dianon Systems   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; CANCER INCIDENCE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SERODIAGNOSIS;

AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS;

EID: 0032169520     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00214-3     Document Type: Article

References (14)

1. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
2. 2. Luderer AA, Chen Y, Soriano TF, et al: Measurement of the proportion of free to total prostate-specific antigen improves diagnostic performance of prostate-specific antigen in the diagnostic grey zone of total prostate specific antigen. Urology 46: 187-194, 1995.
3. 3. Catalona WJ, Smith DS, Wolfer RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. J Am Med Assoc 274: 1214-1220, 1995.
4. 4. Bangma CH, Kranse R, Blijengerg BG, et al: The value of screening tests in the detection of prostate cancer: results of a retrospective evaluation of 1726 men. Urology 46: 779-784, 1995.
5. 5. Prestigiacomo AF, Lilja H, Pettersson K, et al: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 156: 350-354, 1996.
6. 6. Partin AW, Catalona WJ, Southwick PC, et al: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48(suppl 6A): 55-61, 1996.
7. 7. Chen Y, Luderer AA, Thiel RP, et al: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 47: 518-524, 1996.
8. 8. Vashi AR, Wojno KJ, Henricks W, et al: Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 49: 19-27, 1997.
9. 9. Partin AW, Carter HB, Chan DW, et al: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990.
10. 10. Lange PH, Ercole CJ, Lightner DJ, et al: The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141: 873-879, 1989.
11. 11. Hudson HA, Bahnson RR, and Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142: 1011-1017, 1989.
12. 12. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
13. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
14. 14. Catalona WJ, Smith DS, and Ornstein DK: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. J Am Med Assoc 277: 1452-1455, 1997.